Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Supinoxin (RX-5902) 是磷酸化 p68 RNA 解旋酶的强效口服活性抑制剂,是一种抗肿瘤试剂。它与 Y593 磷酸化的 p68 相互作用并减弱 β-catenin 的核穿梭性。它诱导细胞凋亡并抑制 TNBC 癌细胞系的生长,IC50的范围为 10 nM 至 20 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 948 | 现货 | ||
5 mg | ¥ 2,480 | 现货 | ||
10 mg | ¥ 3,730 | 现货 | ||
25 mg | ¥ 5,960 | 现货 | ||
50 mg | ¥ 8,390 | 现货 | ||
100 mg | ¥ 11,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,730 | 现货 |
产品描述 | Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase and a potent first-in-class anti-cancer agent. Supinoxin induces cell apoptosis and inhibits the growth of TNBC cancer cell lines (IC50s:10 nM - 20 nM). |
体外活性 | Supinoxin inhibits cell growth, MDA-MB-231, Caki-1, UMRC2, PANC-1, A549, MKN-45, HepG2, HCT116, HT29, PC-3, U251, HeLa, SK-MEL-28 and OVCAR-3 (IC50: range from 0.01 μM to 0.021 μM in the growth inhibition of cancer cells). Supinoxin (0-10 μM; 72 hours) is active against cell lines of all TNBC molecular subtypes and is active against cell lines with mutations in p53, RB1, CDKN2A, and loss of PTEN. Supinoxin (20-100 nM; 24 hours) treatment causes a dose-dependent increase in tetraploid cells, consistent with induction of G2–M cell-cycle arrest. Supinoxin (0-100 nM; 24 or 48 hours) reduces MCL-1 expression in a dose-dependent manner in TNBC cell lines sensitive to Supinoxin. Supinoxin (0-100 nM; 72 hours) exhibits no significant induction of apoptosis in cell lines resistant to the antiproliferative effects of Supinoxin. But in sensitive cells, the observed activation of apoptosis begins at 24–48 hours and reaches a peak at 72 hours. The induced apoptosis is treated with a dose of 100 nM [1][2]. |
体内活性 | Supinoxin (p.o.; 160/320/600 mg/kg; once weekly for 3 weeks) obviously dose-dependent tumor growth inhibition in the MDA-MB-231 model, exhibits TGI of 55.7%, 80.29% and 94.58% at 160 mg/kg, 320 mg/kg and 600 mg/kg, respectively [1]. |
别名 | RX-5902 |
分子量 | 441.46 |
分子式 | C22H24FN5O4 |
CAS No. | 888478-45-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (226.52 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2652 mL | 11.3261 mL | 22.6521 mL | 56.6303 mL |
5 mM | 0.453 mL | 2.2652 mL | 4.5304 mL | 11.3261 mL | |
10 mM | 0.2265 mL | 1.1326 mL | 2.2652 mL | 5.663 mL | |
20 mM | 0.1133 mL | 0.5663 mL | 1.1326 mL | 2.8315 mL | |
50 mM | 0.0453 mL | 0.2265 mL | 0.453 mL | 1.1326 mL | |
100 mM | 0.0227 mL | 0.1133 mL | 0.2265 mL | 0.5663 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Supinoxin 888478-45-3 Apoptosis Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis breast inhibit PANC-1 Inhibitor HCT116 UMRC2 PC-3 MKN-45 RX5902 TNBC HepG2 RNA helicase HT29 RX-5902 cancer A549 Caki-1 RX 5902 inhibitor